Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Pilsicainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.95 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.45 |
| ▸ | SCN1A | P35498 | 2/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pilsicainide SCHEMBL14809244 | 0.97 | KCNH2 (1.00) | KCNH2ATML3MBTL1POLBSCN3A | |
| Pilsicainide SCHEMBL142244 | 0.97 | KCNH2 (1.00) | KCNH2ATML3MBTL1POLBSCN3A | |
| Pilsicainide SCHEMBL483632 | 0.96 | KCNH2 (0.97) | KCNH2ATML3MBTL1POLBSCN3A | |
| Pilsicainide SCHEMBL14471484 | 0.95 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBSCN3A | |
| Pilsicainide SCHEMBL483631 | 0.95 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBSCN3A | |
| SCHEMBL15551940 | 0.83 | KCNH2 (0.74) | KCNH2L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL10840605 | 0.77 | KCNH2 (0.66) | KCNH2POLBKMT2ALMNAALDH1A1 | |
| Pyrrocaine SCHEMBL1651381 | 0.73 | MEN1 (0.67) | KCNH2ATML3MBTL1POLBMEN1 | |
| SCHEMBL10371948 | 0.72 | KCNH2 (0.58) | KCNH2ATML3MBTL1POLBSCN3A | |
| Pyrrocaine SCHEMBL25718 | 0.70 | MEN1 (0.70) | KCNH2ATML3MBTL1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221286-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2758053-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | Gilead Sciences, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043925-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221286-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | IAPP, SCNN1B, GLP1R | KCNH2 55/4885ATM 3538/4885L3MBTL1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.